James Lipton, MD, PhD
Director of Research
The scientific research department is headed by James Lipton, M.D, Ph.D. A mathematical prodigy at age 13, Dr Lipton was the first to suggest that the universe is 8-dimensional with his thesis, 8 Dimensional Matrix Algebra. He was awarded a Westinghouse Scholarship to Princeton at age 15, where he immediately began teaching a postgraduate seminar on matrices at the Institute for Advanced Study, School of Mathematics.
During Dr Lipton's career as a surgeon, he pioneered several innovative surgical procedures, including credit as the first person to put an inferior vena caval umbrella in a human patient, to prevent the embolism of major clots into the heart and lungs. Dr Lipton has written and published several articles for major scientific and medical journals. He published his first article on tumor immunology at the age of 27 while he served as a surgical intern at Jackson Memorial Hospital, which is the basis behind ongoing research for Macrimmune.™
In 1981 Dr Lipton fulfilled his desire to extend his knowledge of tumor immunology by earning his Doctorate Degree in Pharmacology. He discovered the tumoricidal effects of macroglobulins and began designing drugs to assist the body's immune system in combatting cancer. Dr Lipton's research has resulted in patents pending on 5 major drugs and supplements. After his surgical career, Dr Lipton dedicated his life to cancer research and the fulfillment of Macrimmune™ as a cure for the devastating disease.
« back »
Alex Aller, PhD
Chief Executive Officer
Dr Aller received his Master's Degree from the University of Florida in 1980. He spent the next 9 years working as a business and marketing professional in the medical-scientific industry. He received his Doctorate in Molecular Immunology from the University of Florida College of Medicine in 1997.
Upon graduation, Dr Aller worked as the Assistant Director of the Rumbaugh-Goodwin Institute for Cancer Research. In January 1999 he moved to Birmingham, Alabama as Manager of the Cell Biology and Immunology Group at Southern Research Institute Department of Cancer Therapeutics. In June 2002, he returned to the Rumbaugh-Goodwin Institute for Cancer Research as the Executive Director. He has been involved with several successful start-up biotech firms in the capacity of VP, COO and CEO.
« back »
Board of Directors
Thomas Ross, MSc
Mr Ross specializes in alternative investments to the traditional stock and bond markets. Since 1986 he has been active in early stage private equity capital investments primarily in the Southeast. He is a director of the Gold Coast Venture Capital Association. Tom was the editor for the monthly investment newsletter, The International Financial Strategist, and has led many speaking engagements on investments, asset protection, and emerging company capital finance. He is a Series 7 licensed NASD registered representative, and holds Florida licenses in health and life insurance.
Mr Ross is active as a founder and Director of the Global Alliance for Health Solutions, an organization that provides worldwide research on contemporary and complimentary medicine. He was selected as a 2003 and 2004 Florida Businessman of the Year by the Republican Congressional Committee's Business Advisory Council, and is appointed to the Committee's Presidential Business Commission. Mr Ross has served on the Business Advisory Board for the University of Florida, Center of Excellence for Regenerative Health and Biotechnology, and is President of the nonprofit Palm Beach Business Group.
He is a graduate of Purdue University in Aeronautical Engineering, and an MSc in Industrial Management. After several years researching various defense establishments with Boeing, he began an international career in investments, real estate, and financial planning. He has a background in international corporate management and business development, with investment clients in Europe, the Middle East, and the USA.
« back »
Carson E. Beadle
Mr Beadle has been President of a strategic planning consulting firm since 1998, with clients in the banking, paper, mining, automotive, insurance, and consumer products industries, and medical societies, governments, and universities. He is also a major shareholder and director of a nutraceutical manufacturing and distribution company.
Mr Beadle's primary career was with Marsh & McLennan, serving as Board member of a subsidiary that emphasized employee benefit plans. As Chairman of the American Benefits Council, he helped develop regulatory requirements for benefit plans, giving Congressional testimony on several occasions. He served as Chairman of the Health Committee of the US Chamber of Commerce, the Medical Savings Account Subcommittee of the Business Roundtable, Government Affairs Committee of the Association of Management Consulting Firms, and provided guidance as a member of the Ford Presidential Task Force on Health.
Mr Beadle was also VP of the Leukemia Society of NYC, the Combined Health Appeal of NYC, and the Canadian Cancer Society. He has authored over 100 articles appearing in the Wall Street Journal, New England Journal of Medicine, Fortune, the New York Times and many health and management publications. He is Chairman and Co-Founder of the Health Project, the White House-supported organization that presents the annual C. Everett Koop National Health Award. He is also a founding Director of the Health Enhancement Research Organization of Birmingham, a Board member of Security Mutual Life Insurance Company of NY, and National Security Life and Annuity Trust. He is past-Chair of the Business Forum on Aging, American Society On Aging, the National Academy of Social Security in Washington, and the Economic Club of New York, and a member of the Stanford University Corporate Health Program. He has also served as Chairman of the Steering Committee of the Global Alliance for Health Solutions.
« back »
Leo D. LaGasse, MD
Dr LaGasse is a nationally renowned leader and surgeon in the treatment of gynecologic cancers. He is an expert in all gynecologic cancers, and specializes in uterine preservation and proactive management for recurrent ovarian cancers. Dr LaGasse received his medical degree from the University of Virginia Medical School in 1959. He completed an internship and residency at the UCLA Medical Center. Dr LaGasse is board certified by the American Board of Obstetrics and Gynecology with a subspecialty in gynecologic oncology.
Dr LaGasse is Professor Emeritus in Gynecologic Oncology at the UCLA School of Medicine. He is the founder and Medical Director of Medicine for Humanity, a nonprofit organization dedicated to the improvement of women's health worldwide. He has served on the Board of Directors, American Board of Obstetrics and Gynecology, and was head of the Division of Gynecologic Oncology of the American Board.
Dr LaGasse is the recipient of numerous awards and honors of excellence in the field of cancer research and treatment, and has published numerous publications on cancer. He has served as a member of the Editorial Board for the Journal of Gynecologic Oncology, and others.
« back »
John Lunn, MD, MRCP, FRCP
Dr Lunn is a prominent oncologist, has over 40 years experience in medical science as an academic and practitioner, and participated in early anecdotal trials for Macrimmune.™ He is currently a Consultant Specialist Physician, the Director of Hypertension Clinical Research, and the Director of the Oncology Program at Princess Margaret Hospital in Nassau, Bahamas.
Dr Lunn is currently serving as the President for the Commonwealth Medical Research Institute, and has served as the Medical Director for the Bahamas Cancer Society. He has published papers on hypertension, has been recognized for outstanding contributions in the field of medicine, and was recognized as Physician Emeritus by The Medical Association of The Bahamas.
Dr Lunn became a Member of the Royal College of Physicians (MRCP) and Fellow of Royal College of Physicians (FRCP) at the University of Edinburgh, Scotland. He is an active member of the Association of American Physicians and Surgeons.
« back »
Mark Muller, PhD
Dr Muller received his PhD in Molecular Virology from the University of British Columbia (Vancouver, Canada) in 1977, and has been active in academic science (research and teaching) since his postdoctoral research at the McArdle Laboratory for Cancer Research (University of Wisconsin, Madison) from 1977-1980. Dr Muller was Professor of Molecular Genetics at Ohio State University and a member of the Ohio State Comprehensive Cancer Center. Based on his expertise in translational research, he assumed a leadership role as co-director of the Experimental Therapeutics Program in the NCI-funded Cancer Center until 2004, when he and his research team moved to the University of Central Florida.
Dr Muller is Professor of Molecular Biology and Microbiology at the UCF Burnett College of Biomolecular Sciences, and directs a nationally-funded research group studying gene regulation in cancer.
Dr Muller has published over 80 scientific articles and books, given more than 300 invited lectures and seminars at national and international universities and industries, served on numerous NIH, NCI, and NSF scientific review panels, organized national and international scientific conferences, and edited and reviewed scientific papers for a number of journals.
« back »